非小细胞肺癌GP方案化疗前后肿瘤标志物变化临床意义分析

Analysis on clinical significance in changes of tumor markers in patients with non-small cell lung cancer before and after treatment by GP regimen

目的评估非小细胞肺癌(NSCLC)化疗前后血清癌胚抗原(CEA)、糖类抗原125(CA-125)、血清细胞角质素片段抗原21-1(CYFRA 21-1)变化的临床意义。方法 40例NSCLC患者行吉西他滨+顺铂(GP方案)化疗,根据疗效分为稳定组(26例)和进展组(14例)。在化疗前后,全部清晨空腹采集血清样本,冷冻保存。用电化学发光免疫测定法检测血清CEA、CA-125、CYFRA 21-1的含量水平。结果稳定组化疗后NSCLC患者血清中CEA、CA-125、CYFRA 21-1水平明显低于治疗前(P<0.05)。而进展组化疗前后此3项指标变化无统计学意义(P>0.05)。结论血清CEA、CA-125、CYFRA 21-1联合检测可作为NSCLC化疗疗效的评价指标。

Objective To evaluate clinical significance of serum carcinoembryonic antigen（CEA）,carbohydrate antigen（CA-125）,and cytokeratin fragment antigen 21-1（CYFRA21-1） in patients with non-small cell lung cancer（NSCLC） before and after chemotherapy.Methods According to the effect of chemotherapy,40 patients were divided into two groups： stable group（26 cases） and progressive group（14 cases）.Serum samples of 40 patients diagnosed as NSCLC were collected at fasting condition before and after chemotherapy,then they were cryopreserved.Serum levels of CEA,CA-125 and CYFRA 21-1 were detected by electrochemiluminescence immunoassay.Results Serum levels of CEA,CA-125,and CYFRA21-1 after chemotherapy were significantly lower than those before chemotherapy in patients of stable group（P0.05）,while there was no significant difference in serum levels of CEA,CA-125 and CYFRA 21-1 before and after chemotherapy in patients of progressive group.Conclusion Combined detection of serum levels of CEA,CA-125,and CYFRA21-1 can be considered as predictors of chemotherapeutic effect in NSCLC patients.